{"id":51334,"date":"2017-12-23T17:20:31","date_gmt":"2017-12-23T17:20:31","guid":{"rendered":"https:\/\/www.nationaldrugscreening.com\/?p=51334"},"modified":"2022-11-30T11:11:44","modified_gmt":"2022-11-30T16:11:44","slug":"suggested-policy-addendum-for-new-dot-drug-testing-rule","status":"publish","type":"post","link":"https:\/\/www.nationaldrugscreening.com\/blogs\/suggested-policy-addendum-for-new-dot-drug-testing-rule\/","title":{"rendered":"Suggested Policy Addendum for New DOT Drug Testing Rule"},"content":{"rendered":"\n
This following is not legal advice, it is provided for your information and is a sample addendum to update the DOT Drug & Alcohol Policy in accordance with the new DOT rule effective 01\/01\/2018.<\/strong><\/em><\/p>\n\n\n\n Company Name: <\/strong>_______________________________________________________<\/p>\n\n\n\n DOT Drug & Alcohol Policy Addendum DOT 5 Panel Urine Drug Test<\/strong><\/p>\n\n\n\n As specified in DOT regulations<\/strong> 49 CFR part 40 with the Cut Off levels listed in DOT regulations 49 CFR part 40; the following substances will be tested for:<\/p>\n\n\n\n Some common names for the new semi-synthetic opioids include OxyContin\u00ae, Percodan\u00ae, Percocet\u00ae, Vicodin\u00ae, Lortab\u00ae, Norco\u00ae, Dilaudid\u00ae, and Exalgo\u00ae.<\/p>\n\n\n\n DOT Covered Employees and New Opioids Testing<\/strong><\/p>\n\n\n\n
Dated 01\/01\/2018<\/strong><\/p>\n\n\n\n\n